Skip to main content
Erschienen in:

02.06.2020 | Research Article

Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study

verfasst von: Y. Chu, B. Xu, Q. Song, Q. Hu

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Currently, the role of adjuvant radiotherapy (RT) in the treatment of patients with intestinal-type gastric adenocarcinoma (IGA) has not been well established. This study aimed to elucidate the survival impact of RT on such patients.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database was utilized to select eligible patients. The recruited patients were dichotomized into those not received RT versus those received RT. The 1:1 propensity score matching (PSM) analysis was conducted to balance the confounding factors between the two comparison groups. The categorical variables were assessed by Chi-square test. Cancer-specific survival (CSS) and overall survival (OS) of the patients were compared by Kaplan–Meier (KM) methods. Cox proportional hazard models were used to identify prognostic factors associated with CSS.

Results

A total of 3572 eligible patients were enrolled for our analysis, of which, 2896(81.1%) patients did not receive RT and 676(18.9%) patients received RT. Before PSM, except race and tumor size, significant differences in patients’ baseline characteristics were observed in no RT versus RT group. The KM plots before PSM indicated that RT exerted significant survival benefits for the recruited patients (p < 0.001). After PSM, most confounders were well balanced between the two comparison groups. The KM plots showed significantly superior CSS and OS in the RT group (p < 0.05). Grade IV, stage II–IV, and N3 were identified as independent risk factors, while LN examined > 15 and RT were independent protective factors for favorable prognosis. Subgroup survival analysis revealed that RT brought a significant CSS advantage for the stage IV patients.

Conclusion

Based on PSM analysis of the cohort from SEER database, RT showed significant survival benefits for patients with IGA. Our study supports adjuvant RT for this specific cohort.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386386.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386386.CrossRef
2.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7e34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7e34.CrossRef
3.
Zurück zum Zitat Picado O, Dygert L, Macedo FI, et al. The role of surgical resection for stage IV gastric cancer with synchronous hepatic metastasis. J Surg Res. 2018;232:422–9.CrossRef Picado O, Dygert L, Macedo FI, et al. The role of surgical resection for stage IV gastric cancer with synchronous hepatic metastasis. J Surg Res. 2018;232:422–9.CrossRef
4.
Zurück zum Zitat Perrot-Applanat M, Vacher S, Pimpie C, et al. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol Lett. 2019;18:674–86.PubMedPubMedCentral Perrot-Applanat M, Vacher S, Pimpie C, et al. Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol Lett. 2019;18:674–86.PubMedPubMedCentral
5.
Zurück zum Zitat Kim KY, Yi BR, Lee HR, et al. Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol. 2012;40:1097–104.CrossRef Kim KY, Yi BR, Lee HR, et al. Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol. 2012;40:1097–104.CrossRef
6.
Zurück zum Zitat Pellino A, Riello E, Nappo F, et al. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol. 2019;25:5773–888.CrossRef Pellino A, Riello E, Nappo F, et al. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. World J Gastroenterol. 2019;25:5773–888.CrossRef
7.
Zurück zum Zitat Tian P, Liang C. Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing. Oncol Lett. 2018;15:2057–64.PubMed Tian P, Liang C. Transcriptome profiling of cancer tissues in Chinese patients with gastric cancer by high-throughput sequencing. Oncol Lett. 2018;15:2057–64.PubMed
8.
Zurück zum Zitat Taki T, Hoya Y, Watanabe A, et al. Usefulness of chemoradiotherapy for inoperable gastric cancer. Ann R Coll Surg Engl. 2017;99:332–6.CrossRef Taki T, Hoya Y, Watanabe A, et al. Usefulness of chemoradiotherapy for inoperable gastric cancer. Ann R Coll Surg Engl. 2017;99:332–6.CrossRef
9.
Zurück zum Zitat van den Ende T, Ter Veer E, Machiels M, et al. The efficacy and safety of (neo) adjuvant therapy for gastric cancer: a network meta-analysis. Cancers (Basel). 2019;11:E80.CrossRef van den Ende T, Ter Veer E, Machiels M, et al. The efficacy and safety of (neo) adjuvant therapy for gastric cancer: a network meta-analysis. Cancers (Basel). 2019;11:E80.CrossRef
10.
Zurück zum Zitat Qiu MZ, Shi SM, Chen M, et al. Comparison of HER2 and lauren classification between biopsy and surgical resection samples, primary and metastatic samples of gastric cancer. J Cancer. 2017;8:3531–7.CrossRef Qiu MZ, Shi SM, Chen M, et al. Comparison of HER2 and lauren classification between biopsy and surgical resection samples, primary and metastatic samples of gastric cancer. J Cancer. 2017;8:3531–7.CrossRef
11.
Zurück zum Zitat Azimzadeh-Isfanjani A, Safaralizadeh R, Hosseinpour-Feizi M, et al. Expression of miR-520c in intestinal type gastric adenocarcinoma. J Gastrointest Oncol. 2018;9:1184–9.CrossRef Azimzadeh-Isfanjani A, Safaralizadeh R, Hosseinpour-Feizi M, et al. Expression of miR-520c in intestinal type gastric adenocarcinoma. J Gastrointest Oncol. 2018;9:1184–9.CrossRef
12.
Zurück zum Zitat Ansari S, Gantuya B, Tuan VP, et al. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci. 2018;19:E2424.CrossRef Ansari S, Gantuya B, Tuan VP, et al. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci. 2018;19:E2424.CrossRef
13.
Zurück zum Zitat Ikoma N, Das P, Hofstetter W, et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006–2014 using propensity score matching. Gastric Cancer. 2018;21:1004–133.CrossRef Ikoma N, Das P, Hofstetter W, et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006–2014 using propensity score matching. Gastric Cancer. 2018;21:1004–133.CrossRef
14.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRef Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRef
15.
Zurück zum Zitat Shridhar R, Almhanna K, Hoffe SE, et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis. Cancer. 2013;119:1636–42.CrossRef Shridhar R, Almhanna K, Hoffe SE, et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a surveillance, epidemiology, and end results database analysis. Cancer. 2013;119:1636–42.CrossRef
16.
Zurück zum Zitat Stumpf PK, Amini A, Jones BL, et al. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: a national cancer data base analysis. Cancer. 2017;123:3402–9.CrossRef Stumpf PK, Amini A, Jones BL, et al. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: a national cancer data base analysis. Cancer. 2017;123:3402–9.CrossRef
17.
Zurück zum Zitat Yang J, Chen J, Yang M, et al. Acupuncture for hypertension. Cochrane Database Syst Rev. 2018;11:CD008821.PubMed Yang J, Chen J, Yang M, et al. Acupuncture for hypertension. Cochrane Database Syst Rev. 2018;11:CD008821.PubMed
19.
Zurück zum Zitat Wang Y, Liu W, Yu Y, et al. Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas. Eur Radiol. 2020;30:2934–44.CrossRef Wang Y, Liu W, Yu Y, et al. Potential value of CT radiomics in the distinction of intestinal-type gastric adenocarcinomas. Eur Radiol. 2020;30:2934–44.CrossRef
20.
Zurück zum Zitat Antonelli J, Cefalu M, Palmer N, et al. Doubly robust matching estimators for high dimensional confounding adjustment. Biometrics. 2018;74:1171–9.CrossRef Antonelli J, Cefalu M, Palmer N, et al. Doubly robust matching estimators for high dimensional confounding adjustment. Biometrics. 2018;74:1171–9.CrossRef
Metadaten
Titel
Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study
verfasst von
Y. Chu
B. Xu
Q. Song
Q. Hu
Publikationsdatum
02.06.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 1/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02408-5

Neu im Fachgebiet Onkologie

ePA: Entlastung oder Mehrarbeit?

Die elektronische Patientenakte (ePA) soll das Gesundheitswesen revolutionieren. Mit über 2000 Krankenhäusern und mehr als 100.000 ärztlichen Praxen ist sie eines der größten Digitalisierungsprojekte Europas, wie Florian Fuhrmann präsentierte. Während die Politik die ePA als „Gamechanger“ feiert, zeigt sich in der Praxis ein anderes Bild. 

Mammakarzinom: Bluttest statt Gewebeprobe

Tumore lassen sich heute ohne Gewebeprobe nachweisen – dank Liquid Biopsy. Diese Methode ermöglicht es, zirkulierende Tumorzellen (CTCs) unc zellfreie Tumor-DNA (ctDNA) im Blut zu analysieren. Ihr Einsatz reicht von der Prognose bis hin zum Nachweis eines molekularen Relapses. Welche Rolle sie künftig für therapeutische Entscheidungen spielt, wird aktuell intensiv erforscht.

Ältere Patientinnen mit Mammakarzinom – ist weniger mehr?

Etwa 40 % der Frauen mit Mammakarzinom in Deutschland erkranken nach dem 70. Lebensjahr. Dennoch sind ältere Patientinnen in klinischen Studien häufig unterrepräsentiert. Wie können Betroffene optimal behandelt werden, ohne sie zu übertherapieren oder ihnen durch eine Untertherapie Chancen zu nehmen?  

Kopf-Hals-Tumoren: Die Immuntherapie ist kein Selbstläufer

Ergebnisse einer weiteren Studie legen nahe: Mit einer adjuvanten Immuncheckpointhemmung ist lokal fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereichs nur schwer beizukommen. Einige Fachleute geben die Hoffnung jedoch nicht auf und diskutieren mögliche Gründe für die negativen Ergebnisse.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.